Moderna, Inc.
NMS: MRNALive Quote
📈 ZcoreAI Score
Our AI model analyzes Moderna, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MRNA Z-Score →About Moderna, Inc.
Healthcare
Biotechnology
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
📊 Fundamental Analysis
Moderna, Inc. demonstrates a profit margin of -145.2%, which is below the sector average, suggesting competitive pressure.
The company recently reported -29.8% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -28.9%, which indicates that capital utilization is currently under pressure.
At a current price of $50.96, MRNA currently sits at the 77th percentile of its 52-week range (Range: $22.28 - $59.55).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$20.21B
Trailing P/E
--
Forward P/E
-10.97
Beta (5Y)
1.34
52W High
$59.55
52W Low
$22.28
Avg Volume
10.20M
Day High
Day Low